Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Virax Biolabs Group's share price for the quarter that ended in Sep. 2025 was $15.2025. Virax Biolabs Group's Shares Outstanding (EOP) for the quarter that ended in Sep. 2025 was 0.26 Mil. Therefore, Virax Biolabs Group's market cap for the quarter that ended in Sep. 2025 was $3.98 Mil.
Virax Biolabs Group's quarterly market cap
declined
from Sep. 2024 ($8.44 Mil) to Mar. 2025 ($4.96 Mil) and
declined
from Mar. 2025 ($4.96 Mil) to Sep. 2025 ($3.98 Mil).
Virax Biolabs Group's annual market cap
declined
from Mar. 2023 ($10.78 Mil) to Mar. 2024 ($1.85 Mil) but then
increased
from Mar. 2024 ($1.85 Mil) to Mar. 2025 ($4.96 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Virax Biolabs Group's Enterprise Value for Today is $-0.58 Mil.
Virax Biolabs Group (NAS:VRAX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Virax Biolabs Group Market Cap Related Terms
Virax Biolabs Group Market Cap Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Virax Biolabs Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Virax Biolabs Group's Market Cap for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virax Biolabs Group (VRAX) has a Market Cap of $2.46 Mil as of Jul. 07, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Virax Biolabs Group and its competitors. According to the industry distribution chart, Virax Biolabs Group ranks #1352 out of 1421 companies in the Biotechnology industry, placing it in the top 95.1%.
Is Virax Biolabs Group's Market Cap too high?
Virax Biolabs Group's current Market Cap is $2.46 Mil. The Biotechnology industry median Market Cap is 121.57. Virax Biolabs Group's value of $2.46 Mil is 98% below this industry median. Based on the distribution chart, Virax Biolabs Group ranks #1352 out of 1421 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Virax Biolabs Group has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Market Cap compare to BBLG and PKTX?
According to the Biotechnology industry distribution chart, Virax Biolabs Group ranks #1352 out of 1421 companies for Market Cap. This places Virax Biolabs Group in the lower half of its industry. The industry median Market Cap is 121.57. Virax Biolabs Group's value of $2.46 Mil is 98% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.57, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virax Biolabs Group's current Market Cap of $2.46 Mil is 98% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Virax Biolabs Group and its competitors. For the Biotechnology industry, the median Market Cap is 121.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virax Biolabs Group's current Market Cap is $2.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.15, compared to a current price of $3.09 — trading 168.7% above its estimated fair value. The current Market Cap is $2.46 Mil and 98% below the Biotechnology industry median of 121.57. Virax Biolabs Group's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Market Cap is $2.46 Mil as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued.
The current stock price of $3.09 is trading 168.7% above its estimated GF Value™ of $1.15.
GuruFocus considers Virax Biolabs Group to be Significantly Overvalued.
Key valuation signals for VRAX:
Market Cap: $2.46 Mil
GF Value™: $1.15 vs. price of $3.09 (168.7% above fair value)
Industry Position: 98% below the Biotechnology median (#1352 of 1421)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
37GF Score
Get the complete analysis for VRAX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
